News UroGen’s urothelial cancer drug bags FDA approval The FDA has approved UroGen’s Jelmyto (mitomycin gel) as the first therapy to treat low-grade upper tract urothelial cancer (UTUC).
News JPM: AbbVie pays $650m upfront for RemeGen cancer drug AbbVie joins the ranks of companies developing cancer drugs that target both PD-1 and VEGF, via a $5.6bn licensing deal with China's RemeGen.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
